Independent. No paid rankings. Our evidence grades are never for sale. Where a cosmetic or skincare product passes our review, we may link to it with a disclosed affiliate link. Reviewed weekly Editorial policy Newsletter

Home›Explore peptides›PEG-MGF

PEG-MGF

Written by The Peptide Record editorialClinical review not yet completedLast reviewed 12 September 2026Funding No vendor payment

Mechano growth factor is a real, naturally occurring splice variant of the IGF-1 gene, produced by muscle in response to mechanical stress. PEG-MGF is a synthetic, stabilized version sold as a "recovery peptide" — but a 2026 peer-reviewed review found human trials of it are lacking, and claims that it speeds recovery or improves body composition in people remain unproven.

Evidence grade D: what kinds of studies support the claims on this page, with limits. It is not a verdict on any product. How we grade

On this page

  1. What it is
  2. What the evidence actually covers
  3. The mechanistic distinction that matters
  4. What buyers should know

In brief

Should you care? Yes — the underlying biology (MGF as a natural muscle-repair signal) is real and published; the injectable product sold as "PEG-MGF" has no comparable human evidence behind it.

The short version

  • Mechano growth factor is a real, natural IGF-1 splice variant, produced by muscle in response to mechanical stress or damage.
  • PEG-MGF is a synthetic, PEGylated version engineered to extend that natural signal's very short half-life.
  • Human trials are lacking, per a 2026 peer-reviewed review — the entire evidence base is preclinical.

What it is

Mechano growth factor is the name given to a splice variant of the endogenous IGF-1 gene, first described in muscle tissue responding to mechanical overload or injury — a real, published piece of exercise physiology, distinct from the main circulating IGF-1 isoform. Native MGF has an extremely short biological half-life, which is the commercial rationale for PEG-MGF: attaching a polyethylene glycol chain to slow its clearance and make it viable as an injectable product.

What the evidence actually covers

Preclinical work — cell-culture assays showing PEG-MGF promotes myoblast proliferation and delays satellite-cell differentiation, and rodent models of muscle injury and hypertrophy — is real and published. A 2026 peer-reviewed review of GH-IGF1-axis performance peptides (the same review covering IGF-1 LR3, DOI 10.3389/fendo.2026.1822475) found that human randomized controlled trials of PEG-MGF are lacking, and that claims about recovery or body-composition effects in people remain unproven.

The mechanistic distinction that matters

The same review draws a specific contrast: preclinical data suggest PEG-MGF acts earlier in the muscle-repair process (promoting stem-like satellite-cell proliferation) than IGF-1 LR3, which more directly drives protein synthesis in already-differentiated muscle fibers — a genuinely interesting piece of biology, and one reason the two compounds get sold as a "stack." But this is animal and cell-culture pharmacology, not a demonstrated human effect.

Real biology, no human proof

MGF's existence and role in muscle repair is genuine, published science. That doesn't make PEG-MGF, the injectable product sold online, a proven treatment in people — those are two different claims, and only the first one is settled.

What buyers should know

PEG-MGF is not an approved drug anywhere, has no established human dosing evidence, and — as of the most recent dedicated review available — has never been tested in a published human clinical trial. The biology behind the marketing pitch is real; the human proof it works as sold is not.

What you can do next

References

  1. Review of performance-enhancing GH-IGF1-axis peptides, Frontiers in Endocrinology 2026, DOI 10.3389/fendo.2026.1822475 (PMC13322892) — PEG-MGF human RCTs described as lacking.